In recent years, several beneficial cell samples and microbial strains have been discovered, engineered, and studied, resulting in scientific discoveries and other technological breakthroughs such as vaccines and medicines benefitting communities all around the world. However, several medical products tend to require very low temperatures for storage, making Ultra-Low Freezers increasingly important to maintain their viability.
Data Management has been a hotbed for development and innovation, correlating primarily with
the changing digital landscape. Clinical trial management has been significantly impacted, with the
electronic data capture and GDPR-compliance-led industry now unrecognisable from the paper-document administration methods of the past. This development process extends beyond COVID-19 and has a
noticeable impact on clinical trials.
Biotechnology is a key market segment for Coherent. We provide innovative solutions for academic research, pharma discovery, translational research, clinical testing, and interventional therapeutics. We support these applications with lasers, laser engines, fibers, and fiber optic components.
In the 1990s, the first clinical IVR systems (Interactive Voice Response Systems) were developed in order to randomise patients over the phone, and later, to dispense drug and resupply sites as well.
With the rapid developments in the field of gene therapy, the use of viral vectors, especially AAV, to treat various monogenic, inherited diseases in human patients is gaining momentum. Nonetheless, there are still options to optimise the production of such vectors in mammalian cells.
This year, Merck KGaA Darmstadt, Germany has acquired AmpTec, an internationally active
contract manufacturing company (CMO) with comprehensive services for manufacturing of synthetic RNAs and mRNAs and more than 15 years of experience, with cGMP compliant manufacturing capabilities in development. This marks an exciting new chapter, where our combined expertise will allow us to offer our customers innovative technologies and products to help advance life-enhancing therapeutics.
In clinical trials of new drugs and vaccines, the analysis of peripheral blood mononuclear cells (PBMCs) is increasingly recognized as a valuable tool to get insight into the cellular immune response. These data can be used as surrogates in clinical trials for evaluation and market authorisation of new prophylactic or therapeutic vaccines. The collection of the drawn blood and its transport to an isolation lab is a logistical challenge that requires sophisticated procedures and diligent oversight.
Since virus immunotherapies have the potential to improve therapy responses, we established a platform technology based on Herpes Simplex Virus Type 1 (HSV1). TheraVision constitutes a complete development pipeline including a proprietary HSV1 engineering vector for the modular integration of transgenes, a GMP-compliant production process, and complex preclinical test systems including human tumour and immune cells to demonstrate sensitivity and safety.
Cancer immunotherapy exploits the bodys own immune system to fight against cancer. CAR-T cell therapy is one of the breakthrough approaches that involves re-engineering a patient’s own
T cells to recognize and eradicate cancer.
Early December, Deutsche Börse has started BIOTECH Insight, a new information service on the German biotech industry.